Ufenamate

Ufenamate (CAS No.: 67330-25-0) is a synthetic small molecule classified as an anthranilic acid derivative and commonly referenced as the butyl ester analog of flufenamic acid, positioned in discovery research as a pharmacological probe for inflammation associated with dermatologic biology and barrier injury models; within biomedical research workflows it is primarily categorized as an anti inflammatory research reagent used to interrogate lipid mediator and stress response networks, with literature level evidence indicating modulation of cyclooxygenase linked signaling, including suppression of inducible COX 2 expression in inflammatory skin contexts, and reported photoprotective effects in photoaging related systems where attenuation of erythema and edema has been observed, while additional preclinical observations suggest influence on tissue repair associated signaling such as BMP2 linked regenerative responses in murine cranial defect models, supporting exploratory use in mechanistic studies of inflammation resolution and skin microenvironment remodeling; although detailed quantitative potency metrics are limited in publicly summarized sources for this specific compound, activity for anthranilic acid class anti inflammatory agents is generally investigated across nanomolar to micromolar concentration windows depending on assay format, target engagement strategy, and cellular background, and experimental deployment typically includes stimulated keratinocyte or fibroblast assays, cytokine and eicosanoid profiling, UV induced skin inflammation paradigms, and comparative screening against related nonsteroidal anti inflammatory scaffolds, with concentrations or doses used in experiments typically dependent on specific experimental designs and research objectives.